Sector
- 2026-05-22 CHMP opens the EU access queue
- 2026-05-21 Healthcare PE gets a $21B specialist
- 2026-05-20 EU puts a number on trial competitiveness
- 2026-05-19 FDA tries to make repurposing investable
- 2026-05-15 FDA hold, tau risk and AI drug-discovery capital
- 2026-05-14 Duchenne gene therapy data, China BD scale and FDA repurposing
- 2026-05-13 FDA leadership churn, EU shortage policy and UK medtech reliance
- 2026-05-11 FDA leadership risk, another CNPV approval and Blackstone's EPI bet
- 2026-05-08 Odyssey tests IPO demand, FDA reopens a rare-disease path and inspections get faster
- 2026-05-07 Angelini buys US rare disease, FDA reopens Ebvallo and tests inspections
- 2026-05-06 Bayer buys eyes, CellCentric buys time and Myqorzo clears nHCM
- 2026-05-05 MASH gets segmented, inhaled mRNA stumbles and TED moves subcutaneous
- 2026-05-04 UCB buys Candid, PROTAC gets first FDA label and CBER changes hands
- 2026-05-01 FDA squeezes GLP-1 compounding, ODAC blocks camizestrant and Auvelity expands
- 2026-04-30 Chiesi buys HAE launch, GSK CNS bet fails and FDA pauses Newron
- 2026-04-29 FDA moves trials live, skinny labels hit court and Teva buys neuro
- 2026-04-28 Lilly buys the next edit, EMA opens a device lane and biotech tests IPOs
- 2026-04-27 CRISPR gets its proof point, Sun buys scale and UK biotech stays private
- 2026-04-24 A gene therapy first, a shorter device lag and an nrSPMS opening
- 2026-04-22 Pharma capex hesitates, reimbursement bites and packaging gets strategic
- 2026-04-21 Animal-free filing paths, in vivo CAR-T money and a cleaner tools readthrough
- 2026-04-20 Psychedelics get a fast lane, Roche buys MRD scale and AstraZeneca lands a third COPD win
- 2026-04-18 Genome editing guidance, trial disclosure and a selective IPO window